Related Experiment Video
Updated: Dec 29, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Adenosine Suppresses Cholangiocarcinoma Cell Growth and Invasion in Equilibrative Nucleoside Transporters-Dependent
Kornkamon Lertsuwan1,2, Supathra Phoaubon1, Nathapol Tasnawijitwong3
1Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
Abstract:
Cholangiocarcinoma (CCA) is a lethal disease with increasing incidence worldwide. Previous study showed that CCA was sensitive to adenosine. Thereby, molecular mechanisms of CCA inhibition by adenosine were examined in this study. Our results showed that adenosine inhibited CCA cells via an uptake of adenosine through equilibrative nucleoside transporters (ENTs), instead of activation of adenosine receptors. The inhibition of ENTs by NBTI caused the inhibitory effect of adenosine to subside, while adenosine receptor antagonists, caffeine and CGS-15943, failed to do so. Intracellular adenosine level was increased after adenosine treatment. Also, a conversion of adenosine to AMP by adenosine kinase is required in this inhibition. On the other hand, inosine, which is a metabolic product of adenosine has very little inhibitory effect on CCA cells. This indicates that a conversion of adenosine to inosine may reduce adenosine inhibitory effect. Furthermore, there was no specific correlation between level of proinflammatory proteins and CCA responses to adenosine. A metabolic stable analog of adenosine, 2Cl-adenosine, exerted higher inhibition on CCA cell growth. The disturbance in intracellular AMP level also led to an activation of 5′ AMP-activated protein kinase (AMPK). Accordingly, we proposed a novel adenosine-mediated cancer cell growth and invasion suppression via a receptor-independent mechanism in CCA.
Insights
Adenosine inhibits cholangiocarcinoma (CCA) growth by entering cells through equilibrative nucleoside transporters (ENTs), not by activating receptors. This pathway involves adenosine kinase and impacts AMP levels, suppressing cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cholangiocarcinoma (CCA) is an aggressive cancer with rising global incidence.
- Previous research indicated CCA's sensitivity to adenosine, suggesting therapeutic potential.
Purpose of the Study:
- To elucidate the molecular mechanisms by which adenosine inhibits cholangiocarcinoma (CCA) cell growth.
- To investigate the role of adenosine transporters and receptors in adenosine-mediated CCA inhibition.
Main Methods:
- Investigated adenosine uptake via equilibrative nucleoside transporters (ENTs) and adenosine receptors.
- Utilized NBTI (ENT inhibitor) and receptor antagonists (caffeine, CGS-15943).
- Assessed intracellular adenosine and AMP levels, and 5′ AMP-activated protein kinase (AMPK) activation.
Main Results:
- Adenosine inhibited CCA cells through ENT-mediated uptake, not receptor activation.
- Inhibition of ENTs with NBTI abolished adenosine's effect; receptor antagonists had no impact.
- Intracellular adenosine and AMP levels increased, leading to AMPK activation.
- A metabolically stable adenosine analog, 2Cl-adenosine, showed enhanced inhibition.
Conclusions:
- Adenosine suppresses CCA cell growth and invasion via a novel, receptor-independent mechanism.
- The pathway involves adenosine transport via ENTs, intracellular conversion to AMP, and subsequent AMPK activation.
- Targeting adenosine transport presents a potential therapeutic strategy for cholangiocarcinoma.
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...

